The goal of this proposal is to describe, compare, andexplain variations in Lynch syndrome (LS) screening implementation acrossmultiple healthcare systems and create a comprehensive, customizableorganizational toolkit for implementing LS screening.
PI is Alanna K. Rahm, PhD,MS, LGC, Geisinger Medicine Institute. Site PI is Su-Ying Liang, Ph.D. Collaborating sites include the following:
Andrea N. Burnett-Hartmann, Ph.D.,MPH, Kaiser Permanente Colorado; Mara Epstein, Sc.D., MeyersPrimary Care; Jessica Enzell Hunter, Ph.D., KaiserPermanente Northwest; Christine Y. Lu, Ph.D., HarvardPilgrim Health Care Institute; Pamala Palowski, Pharm.D., HealthPartners; Ravi Sharaf, M.D., NorthwellHealth; and Robert Weil, M.D., Catholic HealthInitiatives.
National Cancer Institute
August 01, 2017
July 31, 2022
Investigator(s): Ellis C. Dillon, Ph.D.
Breast Tumor and Blood markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Investigator(s): Su-Ying Liang, Ph.D.